EUVIMEDEUVIMED entdecken
EditorialKommentar

Switching Between Intravenous and Oral P2Y12 Inhibition

Usman Baber

JACC: Cardiovascular Interventions · 2023

DOI: 10.1016/j.jcin.2022.11.014 ↗

Kurz gefasst

Editorial in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Usman Baber. Beteiligte Einrichtung: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: usman-baber@ouhsc.edu. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAcute Coronary SyndromeHumansTreatment OutcomePlatelet Aggregation InhibitorsTicagrelorAdministration, IntravenousPurinergic P2Y Receptor AntagonistsAdenosine MonophosphateReceptors, Purinergic P2Y12

Stichwörter der Autor:innen

acute coronary syndromecangrelorplatelet inhibition

Substanzen

Platelet Aggregation InhibitorsTicagrelorPurinergic P2Y Receptor AntagonistsAdenosine MonophosphateReceptors, Purinergic P2Y12

Autor:innen und Institutionen

  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: usman-baber@ouhsc.edu.

Zitieren

APA

Baber, U. (2023). Switching Between Intravenous and Oral P2Y12 Inhibition. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2022.11.014

Vancouver

Baber U. Switching Between Intravenous and Oral P2Y12 Inhibition. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2022.11.014

BibTeX
@article{Baber2023,
  author = {Baber, Usman},
  title = {Switching Between Intravenous and Oral P2Y12 Inhibition},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  doi = {10.1016/j.jcin.2022.11.014}
}
Kostenlos starten →